ReviewResearch (Washington, D.C.)2024

Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy.

Shengbo Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.